Condition category
Respiratory
Date applied
19/06/2017
Date assigned
20/06/2017
Last edited
16/10/2017
Prospective/Retrospective
Prospectively registered
Overall trial status
Ongoing
Recruitment status
Recruiting

Plain English Summary

Lay summary under review with external organisation

Trial website

Contact information

Type

Public

Primary contact

Mr Nick Woznitza

ORCID ID

http://orcid.org/0000-0001-9598-189X

Contact details

Radiology Department
Homerton University Hopsital
Homerton Row
London
E9 6SR
United Kingdom
+44 208 510 5315
nicholas.woznitza@nhs.net

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

34539

Study information

Scientific title

Impact of radiographer immediate reporting of chest X-rays from general practice on the lung cancer pathway

Acronym

radioX

Study hypothesis

Immediate reporting of chest X-rays from general practice will reduce the time to diagnosis of lung cancer.

Ethics approval

London – Brent REC, 05/06/2017, ref: 17/LO/0870

Study design

Randomised; Interventional; Design type: Diagnosis, Process of Care, Imaging

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Specialty: Health services and delivery research, Primary sub-specialty: Health Services and Delivery Research; UKCRC code/ Disease: Cancer/ Malignant neoplasms of respiratory and intrathoracic organs, Respiratory/ Other diseases of the respiratory system

Intervention

Participants are randomly allocated to one of two groups using block randomisation at session (half day level).

Group 1: Participants receive immediate reporting of chest X-rays referred by general practice, with CT chest when indicated.

Group 2: Participants receive the standard level of care. This includes the routine reporting of chest X-rays referred by general practice.

Participants are followed up to see how long it takes to diagnose lung cancer or how long it took to be discharged from the lung cancer pathway and to evaluate the effectiveness of immediate reporting of chest X-rays by general practice.

Intervention type

Other

Phase

Drug names

Primary outcome measures

Time (in days) to decision to treat (with intermediate time points) for lung cancer or discharge from the lung cancer pathway is measured using patient records at the time where there is a decision to treat or to be discharged from the lung cancer pathway.

Secondary outcome measures

1. Number of CT scans requested is measured using the number of CT chest scans through Radiology Information System at study completion
2. Survival is measured using aggregate data from cancer waiting time reporting at six and 12 months
3. Emergency admissions are measured using data from cancer waiting time reporting at study completion
4. Performance status is measured using data from cancer waiting time reporting at time of decision to treat
5. Number of urgent respiratory cancer referrals are measured from respiratory department records at study completion
6. Relative accuracy and usefulness of chest X-rays reporting by radiographers and consultant radiologists are measured using index diagnosis of thoracic radiologist and/or CT chest within 2 weeks of chest X-ray
7. Number of first 2WW appointments with all radiology results measured using clinician recorded data at time of appointment
8. Cost-effectiveness is measured using QALYS (Quality adjusted life years) at study completion
9. Patient satisfaction is measured using patient questionnaires at two weeks after chest x-ray

Overall trial start date

11/07/2016

Overall trial end date

30/01/2019

Reason abandoned

Eligibility

Participant inclusion criteria

1. Patients referred for a chest X-ray from general practice
2. Over 16 years

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

Planned Sample Size: 4000; UK Sample Size: 4000

Participant exclusion criteria

1. Active diagnosis of lung cancer
2. Aged under 16 years
3. Chest X-rays referrals from any other practitioner (Emergency Department, Inpatient, Outpatient)

Recruitment start date

01/07/2017

Recruitment end date

30/06/2018

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Hometon University Hospital NHS Foundation Trust
Homerton Row
London
E9 6SR
United Kingdom

Sponsor information

Organisation

Canterbury Christ Church University

Sponsor details

N Holmes Road
Canterbury
Canterbury
CT1 1QU
United Kingdom

Sponsor type

Hospital/treatment centre

Website

Funders

Funder type

Government

Funder name

Cancer Research UK

Alternative name(s)

CRUK

Funding Body Type

private sector organisation

Funding Body Subtype

other non-profit

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Trial protocol to be submitted for peer review August 2017. Final results planned publication in a high-impact peer reviewed journal June 2019.

IPD sharing statement:
The current data sharing plans for the current study are unknown and will be made available at a later date

Intention to publish date

30/06/2019

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

16/10/2017: Internal review. 11/08/2017: Internal review.